SUDEEPPHRM Q3 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹172 Cr
verified against source
Revenue YoY
52%
reported change
EBITDA
₹66.8 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Sudeep Pharma delivered an exceptional Q3 FY26 with revenue surging 52% YoY to ₹179.2 crore, driven by robust performance across both business verticals and export markets. EBITDA grew 60% YoY to ₹66.8 crore with 37.3% margin, while PAT expanded 66% YoY to ₹47.7 crore. The specialty ingredients segment now contributes 41% of quarterly revenue, up from under 10% in FY23, reflecting successful diversification into encapsulated and premix products with major global customers. New customer wins include a tier-1 t-tier manufacturer and the world's largest baked goods company. The battery materials platform is gaining traction with 34 active customers (70% validated), and the Deage facility remains on track for early 2027 commissioning. The Nandiseri greenfield (51,200 MT capacity) will commission in March 2026. Management targets sustained growth and stable margins for FY27, with battery materials contributing meaningfully from FY28. Key risks include margin compression from NSS integration costs and timing of utilization ramp at new facilities.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects to sustain the growth trajectory achieved in FY26 (38% YoY for 9 months) into FY27 as well, with stable margins in the 35-37% range.
- Deage battery materials facility (25,000 MT phase-1 capacity) remains on track for commissioning in early 2027, with total project capex of ₹300 crore for phase-1 out of ₹550-600 crore for full 100,000 MT.
- The 51,200 MT facility for gluconates, glycinates, and citrates will commission next month (March 2026); ramp-up expected in H2 FY26 with meaningful contribution in FY28, targeting 30-40% utilization.
- Currently at 35-40% utilization with recent approvals from leading infant nutrition and bakery companies; management targets optimal utilization levels within the next two years.
Risks flagged
- Year-to-date EBITDA margin declined 150 bps to 37.6% from 39.1% in 9M FY25, reflecting integration costs and new facility ramp-up expenses. CFO acknowledged margin remains in 35-37% range.
- Despite 34 active customer engagements, battery materials will only begin contributing revenue in FY28, creating an 18-month gap before offtake translates to sales. Depreciation and interest will only hit from FY28.
- Analyst raised question about customer volume uptake and working capital requirements. Management deflected working capital specifics, stating only that networking capital days remain at ~180 days without detailed inventory/receivables breakdown.
- New Nandiseri facility faces 6-12 month customer approval cycles before material revenue contribution, with management explicitly stating FY28 as the year for meaningful scaling.
Key quotes
- We are the first company globally to offer an ex-China source of battery grade iron phosphate and this differentiation is resonating strongly with customers across the battery value chain.
- We have not taken a margin hit or margin dilution by accepting the tariff impact. Majority, I would say at least across 90% of the business where tariff was effective, we have passed on the tariff impact to the customer.
- What I can say is the growth that we've done over the last couple of years is what we will continue to sustain with a very stable and similar margin profile.
Research modules